Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/49333
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVansteenkiste, J-
dc.contributor.authorDemedts, I-
dc.contributor.authorCUPPENS, Kristof-
dc.contributor.authorPons-Tostivint, E-
dc.contributor.authorWauters , E-
dc.contributor.authorBorm, FJ-
dc.contributor.authorSibille, A-
dc.contributor.authorColinet, B-
dc.contributor.authorPérol, M-
dc.contributor.authorTheelen, WSME-
dc.contributor.authorBiesma, B-
dc.contributor.authorvan de Kerkhove, C-
dc.contributor.authorBuchmeier, E-
dc.contributor.authorAlthoff, FC-
dc.contributor.authorDerijcke, S-
dc.contributor.authorMoro-Sibilot, D-
dc.contributor.authorLaulagnier, K-
dc.contributor.authorHalioua, E-
dc.contributor.authorLevy, L-
dc.contributor.authorGenin, M-
dc.contributor.authorMichel, S-
dc.contributor.authorDedry, C-
dc.contributor.authorDuchayne, C-
dc.contributor.authorCollodoro, M-
dc.contributor.authorRenard, F-
dc.contributor.authorAdriaenssens, S-
dc.contributor.authorDe Vos , B-
dc.contributor.authorCantero, F-
dc.contributor.authorPlumas, J-
dc.contributor.authorSkrzypski, M-
dc.date.accessioned2026-06-17T11:02:23Z-
dc.date.available2026-06-17T11:02:23Z-
dc.date.issued2025-
dc.date.submitted2026-06-17T10:15:45Z-
dc.identifier.citationESMO open, 10 (11) (Art N° 105844)-
dc.identifier.urihttp://hdl.handle.net/1942/49333-
dc.description.abstractWhile immune checkpoint inhibitors have revolutionized the treatment of non-small-cell lung cancer (NSCLC), many patients still suffer from either primary or acquired treatment resistance. Stimulation of antitumor cellular immunity with a therapeutic cancer vaccine in combination with anti-programmed cell death (ligand) protein 1 [PD-(L)1] may improve outcome. PDC∗lung01 is a cancer vaccine made of irradiated plasmacytoid dendritic cells loaded with six NSCLC tumor antigens (NY-ESO-1, MAGE-A3, MAGE-A4, Multi-MAGE-A, MUC1, and Survivin), and available as a ready-to-use product.-
dc.description.sponsorshipFUNDING This work was supported by the Walloon Region, Belgium [grant number 7823] and PDC*line Pharma (no grant number).-
dc.language.isoen-
dc.publisherELSEVIER-
dc.rights2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).-
dc.subject.othertherapeutic cancer vaccine-
dc.subject.otherplasmacytoid dendritic cells-
dc.subject.otherimmune checkpoint inhibitor-
dc.subject.othernon-small-cell lung cancer-
dc.subject.otherclinical trials phase I/II-
dc.titleInnovative therapeutic cancer vaccine PDC*lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer-
dc.typeJournal Contribution-
dc.identifier.issue11-
dc.identifier.volume10-
local.format.pages11-
local.bibliographicCitation.jcatA1-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr105844-
dc.identifier.doi10.1016/j.esmoop.2025.105844-
dc.identifier.pmid41101155-
dc.identifier.isi001599984300001-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.fullcitationVansteenkiste, J; Demedts, I; CUPPENS, Kristof; Pons-Tostivint, E; Wauters , E; Borm, FJ; Sibille, A; Colinet, B; Pérol, M; Theelen, WSME; Biesma, B; van de Kerkhove, C; Buchmeier, E; Althoff, FC; Derijcke, S; Moro-Sibilot, D; Laulagnier, K; Halioua, E; Levy, L; Genin, M; Michel, S; Dedry, C; Duchayne, C; Collodoro, M; Renard, F; Adriaenssens, S; De Vos , B; Cantero, F; Plumas, J & Skrzypski, M (2025) Innovative therapeutic cancer vaccine PDC*lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer. In: ESMO open, 10 (11) (Art N° 105844).-
item.accessRightsOpen Access-
item.contributorVansteenkiste, J-
item.contributorDemedts, I-
item.contributorCUPPENS, Kristof-
item.contributorPons-Tostivint, E-
item.contributorWauters , E-
item.contributorBorm, FJ-
item.contributorSibille, A-
item.contributorColinet, B-
item.contributorPérol, M-
item.contributorTheelen, WSME-
item.contributorBiesma, B-
item.contributorvan de Kerkhove, C-
item.contributorBuchmeier, E-
item.contributorAlthoff, FC-
item.contributorDerijcke, S-
item.contributorMoro-Sibilot, D-
item.contributorLaulagnier, K-
item.contributorHalioua, E-
item.contributorLevy, L-
item.contributorGenin, M-
item.contributorMichel, S-
item.contributorDedry, C-
item.contributorDuchayne, C-
item.contributorCollodoro, M-
item.contributorRenard, F-
item.contributorAdriaenssens, S-
item.contributorDe Vos , B-
item.contributorCantero, F-
item.contributorPlumas, J-
item.contributorSkrzypski, M-
item.fulltextWith Fulltext-
crisitem.journal.eissn2059-7029-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
main.pdfPublished version2.66 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.